Blastic Plasmacytoid Dendritic Cell Neoplasm
Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!
VJHemOnc recently attended the 2025 ASCO Annual Meeting in Chicago, IL, where we gained insights into the latest advancements in…
Date: 30th June 2025
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone…
Date: 18th December 2024
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care
In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute,…
Date: 28th November 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix,…
Date: 6th November 2024
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions…
Date: 3rd June 2024
Updates, challenges and novel agents being explored in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain…
Date: 25th January 2024
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many…
Date: 19th February 2021
